Wednesday, July 19, 2023
Mabwell has announced the approval of clinical trial application for 9MW2921 by the National Medical Products Administration (NMPA) for the treatment of advanced solid tumours. 9MW2921 is developed by Mabwell's novel antibody-drug conjugate plateform IDDC™.
9MW2921 is an advanced antibody-drug conjugate (ADC) that has been developed using the IDDC™ (Interchain-Disulfide Drug Conjugate) platform specifically for the treatment of solid tumours.
9MW2921 exhibits specific binding to antigens present on the cell membrane surface of tumour cells. This specific binding is facilitated by the antibody component of the ADC, which recognises and attaches to the target antigens.
9MW2921 is a pharmaceutical compound that possesses several desirable characteristics. It is characterised by a stable structure, homogeneous composition, and high purity, making it suitable for industrial scale-up.
9MW2921 demonstrates an improved bystander killing effect. The bystander effect refers to the ability of a drug to induce cell death in neighbouring cells, even if they do not directly interact with the drug. By enhancing this effect, 9MW2921 can increase its overall efficacy by attacking not only the target cells but also the surrounding tumour microenvironment